TNF-alpha, recombinant murine protein: Precision Tool for Apoptosis & Inflammation Models

Executive Summary: TNF-alpha recombinant murine protein is a 157-amino acid cytokine expressed in Escherichia coli, corresponding to the soluble extracellular domain of murine TNF-alpha (17.4 kDa) and supplied as a sterile, lyophilized powder (ApexBio P1002)[1]. It is biologically active as a trimer, with an ED50 < 0.1 ng/mL in L929 cytotoxicity assays, indicating specific activity >1.0 × 10⁷ IU/mg in the presence of actinomycin D[1]. The product is non-glycosylated yet retains activity comparable to native forms, making it ideal for dissecting TNF receptor signaling, apoptosis, and inflammation without confounding glycosylation effects[1][2]. Recent studies confirm that TNF-alpha-induced apoptosis can be mechanistically separated from transcriptional shutdown, enabling precise interrogation of cell death pathways[2][3]. The protein's high purity, stability, and lot-to-lot reproducibility support robust, reproducible research outcomes in disease modeling and mechanistic studies[1].

Biological Rationale

Tumor necrosis factor alpha (TNF-alpha) is a prototypical cytokine in the TNF superfamily. It is produced chiefly by activated macrophages and plays essential roles in immune regulation, inflammation, and programmed cell death (apoptosis)[1]. In murine models, TNF-alpha is a critical effector in both host defense and pathological conditions such as cancer, neuroinflammation, and autoimmune diseases[4]. TNF-alpha acts primarily via two cell-surface receptors, TNFR1 and TNFR2, expressed on most mammalian cell types[1][4]. Signaling through these receptors orchestrates diverse outcomes, including cell survival, NF-κB activation, inflammatory gene expression, and, under certain contexts, induction of apoptotic or necroptotic cell death[1][2]. The recombinant murine TNF-alpha protein provides a standardized and reproducible means to activate these pathways in vitro, bypassing variability seen with serum-derived or glycosylated cytokines[1].

Mechanism of Action of TNF-alpha, recombinant murine protein

This recombinant TNF-alpha consists of the soluble 157 amino acid extracellular domain, corresponding to residues 80–235 of the full-length transmembrane precursor[1]. Once reconstituted, it forms a stable, non-glycosylated trimeric complex, which is the biologically active configuration[1][5]. Upon binding to TNFR1 or TNFR2, the complex initiates intracellular signaling cascades, including recruitment of adaptor proteins (e.g., TRADD, TRAF2) and activation of caspases, leading to apoptosis[1][2]. TNF-alpha can also activate canonical NF-κB pathways, promoting inflammatory gene expression and cell survival, depending on cellular context and co-factors[1][2][6].

• ED50 (cytotoxicity, L929 cells, actinomycin D): <0.1 ng/mL (PBS, pH 7.2, 37°C, 24 h)[1].
• Specific activity: >1.0 × 10⁷ IU/mg[1].
• Non-glycosylated, E. coli-expressed: Ensures absence of eukaryotic glycan structures, facilitating mechanistic studies of protein–protein interactions[1].

Evidence & Benchmarks

• Recombinant murine TNF-alpha (soluble, 157 aa, non-glycosylated) induces apoptosis in L929 fibroblast cells at <0.1 ng/mL in the presence of actinomycin D, confirming high biological activity (ApexBio P1002).
• TNF-alpha-induced cell death occurs independently of transcriptional shutdown, as demonstrated by Pol II degradation-dependent apoptotic response (PDAR) in mammalian cells (Harper et al., 2025, see graphical abstract).
• Use of recombinant murine TNF-alpha enables direct dissection of TNF receptor signaling and apoptosis, as described in advanced workflows (TNF-alpha Recombinant: Precision in Apoptosis).
• The product retains activity comparable to native glycosylated TNF-alpha, making it suitable for both basic and translational studies (TNF-alpha Recombinant: Decoding Apoptosis).
• Storage at -20 to -70°C for up to 12 months preserves integrity and activity, as confirmed by stability assays (ApexBio P1002).

Applications, Limits & Misconceptions

Recombinant murine TNF-alpha is widely used in:

• Apoptosis research: Elucidating caspase-dependent and independent cell death mechanisms[1][2].
• Inflammatory disease modeling: Inducing cytokine storms or chronic inflammation in vitro and in vivo[1][4].
• Cancer research: Exploring TNF-mediated tumor cell lysis, immune modulation, and synergy with chemotherapeutics[2][6].
• Neuroinflammation studies: Probing microglial and neuronal responses to TNF receptor activation[4].
• Transcription-independent cell death: Dissecting pathways such as PDAR, where apoptosis is uncoupled from mRNA decay (Harper et al., 2025).

For a comparative guide on workflows and troubleshooting, see TNF-alpha Recombinant Murine Protein: Precision in Apoptosis. This article uniquely contextualizes TNF-alpha use in light of recent discoveries on cell death independent of transcriptional shutdown, extending previous analyses such as TNF-alpha Recombinant: Decoding Apoptosis by integrating PDAR mechanisms.

Common Pitfalls or Misconceptions

• Misconception: TNF-alpha-induced apoptosis always requires active transcriptional shutdown. Correction: Apoptosis can proceed via PDAR, independently of mRNA decay (Harper et al., 2025).
• Pitfall: Assuming glycosylation is necessary for activity. Correction: Non-glycosylated, E. coli-expressed protein retains full biological function in standard assays[1].
• Pitfall: Repeated freeze-thaw cycles. Correction: Aliquot after reconstitution and store at ≤ -20°C to preserve activity (ApexBio P1002).
• Limitation: Product is for research use only and not validated for diagnostic or therapeutic applications[1].
• Boundary: Activity benchmarks are established in the presence of actinomycin D; conditions without inhibitors may yield different EC50 values[1].

Workflow Integration & Parameters

• Formulation: Lyophilized white powder; reconstitute in sterile water or buffer (0.1% BSA recommended) to 0.1–1.0 mg/mL[1].
• Filtration: Supplied from 0.2 μm filtered PBS, pH 7.2[1].
• Storage: -20 to -70°C (lyophilized, ≤12 months); ≤ -20°C (reconstituted, ≤3 months); 2–8°C (reconstituted, ≤1 month)[1].
• Usage: Avoid repeated freeze-thaw cycles. Aliquot after reconstitution for single-use applications[1].
• Assay compatibility: Validated in L929 cytotoxicity assays, immune activation protocols, and cytokine synergy models[1][6].

For details on integrating this protein into advanced apoptosis or immune signaling workflows, consult TNF-alpha Recombinant: Unraveling Cell Death, which this article extends by emphasizing PDAR and transcription-independent mechanisms.

Conclusion & Outlook

TNF-alpha, recombinant murine protein (P1002) is a robust, highly active cytokine standard for dissecting apoptosis and inflammation in murine models. It enables precise activation of TNF receptor pathways, facilitating studies of cell death and immune modulation independently from transcriptional shutdown. Recent evidence, such as the discovery of PDAR, highlights the importance of transcription-independent apoptotic signaling, which can be interrogated using this reagent (Harper et al., 2025). Its stability, defined activity, and compatibility with modern cell culture and disease modeling workflows make it indispensable for advanced mechanistic research in cancer, inflammation, and immunology.

For further technical guidance and comparative analyses, see TNF-alpha Recombinant: Deciphering Non-Transcriptional Cell Death, which details direct interrogation strategies for TNF signaling pathways.